Ultragenyx Pharmaceutical (RARE) Garnering Bullish Sentiment With Forthcoming GTX-102 Phase 3 Angelman Trial

On April 16, Morgan Stanley accrued the terms people for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) from $50 to $67, resulting successful an adjusted upside imaginable successful excess of 178% astatine the prevailing level. The steadfast besides reiterated its Outperform standing connected the stock.

Nestor Rizhniak/Shutterstock.com

Morgan Stanley revised the terms people upward based connected a strict caller probability-of-success attack to the forthcoming GTX-102 Phase 3 Angelman trial. This large objective readout is anticipated successful the 2nd fractional of 2026. The resulting hazard illustration is alternatively asymmetrical. The steadfast has projected a 50% to 70% upside, which importantly offsets a 20% downside hazard of a objective failure.

Back connected March 30, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced clearance from the US Food & Drug Administration for the Investigational New Drug Application for UX016. It is simply a prodrug of sialic acerb nether probe for usage arsenic a substrate replacement therapy for GNE Myopathy. GNEM is simply a uncommon neuromuscular illness characterized by terrible disablement owed to mutations successful the GNE gene, which impairs sialic acerb biosynthesis.

The UX016 programme is supported externally via proof-of-concept objective trials, which see a Phase 1/2 proceedings scheduled for initiation successful the second fractional of 2026. Commenting connected the advancement of UX016, CEO Emil Kakkis observed that moving the cause into the session is simply a important measurement for the GNE myopathy community, and it demonstrates the company’s effort to make a caller method for improving sialic acerb utilization by the muscles. The first-in-human survey volition impact astir 24 patients betwixt 18 and 55 years of property suffering from GNEM, who volition beryllium recruited successful the US.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) develops caller therapies, with a absorption connected identifying, acquiring, and commercializing products for uncommon and ultra-rare familial diseases. It has a beardown accent connected cistron therapy and covers assorted stages of objective trials. The institution is presently going done precocious currency pain with the purpose of turning profitable from 2027 onwards.

While we admit the imaginable of RARE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.